Press Releases

Date Title
June 19, 2020 Progenity Announces Pricing of Initial Public Offering
SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc . (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the pricing of its initial public offering of 6,666,667 shares of common
May 27, 2020 Progenity Shares Posters Identifying Key Factors for Clinical Decision Making
The four posters were released for the 2020 American College of Medical Genetics and Genomics’ (ACMG) Annual Clinical Genetics Meeting. SAN DIEGO, May 27, 2020— Progenity, a biotechnology company with an established track record of success in developing and commercializing molecular testing
May 26, 2020 Progenity Adds Operational Expertise to Leadership Team with Appointment of Damon Silvestry as COO
Mr. Silvestry will be focused on delivering operational excellence, achieving ambitious growth targets, and driving the company’s service culture. SAN DIEGO, May 26, 2020— Progenity, a biotechnology company with an established track record of success in developing and commercializing molecular
March 30, 2020 Progenity Appoints Troy Seelye as CIO
Mr. Seelye will help to strengthen our technology and data strategy, leading the development of key products and services designed to transform the customer experience. SAN DIEGO, March 30, 2020— Progenity, a biotechnology company with an established track record of success in developing and
March 26, 2020 Progenity Offers Enhanced Services During the COVID-19 Pandemic
Our lab is fully operational and we are offering assisted patient education and collection services to support healthcare providers and patients. Recent public health measures related to the novel coronavirus are greatly impacting healthcare practices.
February 5, 2020 Sharing clinical laboratory experience at SMFM 2020
We will present results from clinical laboratory experience that indicate noninvasive prenatal testing (NIPT) performs well for predicting aneuploidies in twin pregnancies. SAN DIEGO – February 5, 2020  – Progenity, developing precision medicine solutions across genomic/epigenomic, proteomic, and
January 8, 2020 Progenity Featured in Gastroenterology & Endoscopy News
Highlighting our work to improve the diagnosis and management of patients with small intestinal bacterial overgrowth (SIBO). Progenity was featured in  Gastroenterology & Endoscopy News  for our work on a capsule that improves the diagnosis and management of patients with small intestinal bacterial
December 10, 2019 Progenity and Geisinger Publish First Study of Primary, Case-Based Data on Economic Burden of Preeclampsia
SAN DIEGO and DANVILLE, Pa.  – December 10, 2019 – Progenity, a privately held biotechnology company, and  Geisinger , one of the nation’s most innovative health services organizations, announced publication of a study in  Obstetrics & Gynecology  demonstrating the significant economic burden
November 19, 2019 Progenity to Present at Piper Jaffray 31st Annual Healthcare Conference
SAN DIEGO, November 19, 2019  – Progenity, Inc. announced today that we'll be participating in the Piper Jaffray 31st Annual Healthcare Conference in New York, December 3 – 5. Progenity’s chief executive officer, Harry Stylli, PhD, will present a corporate overview on Wednesday, December 4, from
October 29, 2019 Progenity Presents Data at ACG 2019
Highlighting Opportunities for Technologies Aimed at Improving Diagnosis and Treatment of Gastrointestinal Disorders SAN DIEGO, October 29, 2019  – Progenity, Inc., a privately held biotechnology company, presented three posters this week at the 2019 American College of Gastroenterology Annual
Displaying 11 - 20 of 35